The present invention relates generally to a novel class of pyrimidinones of Formula (I):
1
that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.